Patents Represented by Attorney, Agent or Law Firm Dennis A. Bennett
  • Transcriptional enhancer from milk protein genes
    Patent number: 6004805
    Abstract: The invention relates to novel enhancer nucleotide sequences which stimulate transcription of heterologous DNA in cells in culture. The enhancers are derived from major milk protein genes by the process of deletion mapping and functional analysis. The invention also relates to expression vectors containing the novel enhancers.
    Type: Grant
    Filed: May 29, 1992
    Date of Patent: December 21, 1999
    Assignee: G.D Searle & Co.
    Inventors: Gerald F. Casperson, Christian T. Schmidhauser, Mina J. Bissell
  • Ex-vivo expansion of stem cells using combinations of interleukin-3 (IL-3) variants and other cytokines
    Patent number: 5997860
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: November 15, 1995
    Date of Patent: December 7, 1999
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
  • Co-administration of interleukin-3 mutants with colony stimulating factors
    Patent number: 5997857
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 7, 1999
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
  • Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
    Patent number: 5985862
    Abstract: The present invention discloses novel pharmaceutical compositions having steroid nitrate ester(ONO.sub.2) derivatives, and to their use treating undesired smooth muscle contractions and inflammatory diseases.
    Type: Grant
    Filed: May 2, 1996
    Date of Patent: November 16, 1999
    Assignee: G.D. Searle & Co.
    Inventors: Foe S. Tjoeng, Mark G. Currie, Mark E. Zupec
  • Assembly-deficient herpesvirus vaccine
    Patent number: 5972666
    Abstract: A vaccine is described which comprises an assembly-deficient herpesvirus. The mutant herpesvirus is capable of infecting and undergoing DNA replication in the cells of a susceptible mammal, but is defective in capsid assembly and formation of mature virion particles. The assembly-deficient herpesvirus is avirulent and capable of generating a protective immune response in a vaccinated mammal.
    Type: Grant
    Filed: July 26, 1996
    Date of Patent: October 26, 1999
    Assignee: G. D. Searle & Co.
    Inventors: Paul J Hippenmeyer, Anne M Rankin, Verne A Luckow
  • Human guanylin
    Patent number: 5969097
    Abstract: A novel pentadecapeptide is disclosed which is useful for the control of intestinal fluid absorption and that has the following amino acid sequencePro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala- 1 5 10 - Ala-Cys-Thr-Gly-Cys (SEQ ID NO.
    Type: Grant
    Filed: June 23, 1992
    Date of Patent: October 19, 1999
    Assignee: G. D. Searle & Co.
    Inventors: Roger C. Wiegand, Mark G. Currie, Kam Fook Fok
  • Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
    Patent number: 5945408
    Abstract: The current invention discloses hydroxyamidino derivatives useful as nitric oxide synthase inhibitors.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: August 31, 1999
    Assignee: G.D. Searle & Co.
    Inventors: R. Keith Webber, Foe S. Tjoeng, Robert E. Manning
  • Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
    Patent number: 5919787
    Abstract: The current invention discloses aminotetrazole derivatives useful as nitric oxide synthase inhibitors.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: July 6, 1999
    Assignee: G. D. Searle & Co.
    Inventors: E. Ann Hallinan, Donald W. Hansen, Jr., Sofya Tsymbalov
  • Method of inhibiting intimal hyperplasia
    Patent number: 5914316
    Abstract: A method is disclosed for inhibiting intimal hyperplasia in a warm-blooded mammal which comprises administering topically at the site and time of a vascular injury induced by arterial intervention in said mammal a small but inhibitorily effective amount of tissue factor pathway inhibitor (TFPI) sufficient to inhibit said intimal hyperplasia.
    Type: Grant
    Filed: September 25, 1996
    Date of Patent: June 22, 1999
    Assignee: Washington University
    Inventors: David M. Brown, Tze-Chein Wun, Roger K. Khouri
  • Azepine derivatives useful as nitric oxide synthase inhibitors
    Patent number: 5883251
    Abstract: The current invention discloses azepine derivatives useful as nitric oxide synthase inhibitors.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: March 16, 1999
    Assignee: G. D. Searle & Co.
    Inventors: Donald W. Hansen, Jr., E. Ann Hallinan, Timothy J. Hagen, Steven W. Kramer, Suzanne Metz, Karen B. Peterson, Dale P. Spangler, Mihaly V. Toth, Kam F. Fok, Arija A. Bergmanis, R. Keith Webber, Mahima Trivede, Foe S. Tjoeng, Barnett S. Pitzele
  • Orthopedic nasal airway appliance
    Patent number: 5861001
    Abstract: Disclosed is a novel orthopedic device for opening a patient's nasal airway.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: January 19, 1999
    Inventor: Robert Katsev
  • Therapeutic methods using fusion proteins between interleukin-3 (IL-3) variants and other hematopoietic factors
    Patent number: 5858347
    Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 12, 1999
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
  • Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
    Patent number: 5854251
    Abstract: Aminotetrazole derivatives of the formula (I) wherein the variables are as defined in the disclosure are useful as nitric oxide synthase inhibitors.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: December 29, 1998
    Assignee: G. D. Searle & Co.
    Inventors: Ann E. Hallinan, Donald W. Hansen, Jr., Sofya Tsymbalov
  • Amidino dervatives useful as nitric oxide synthase inhibitors
    Patent number: 5854234
    Abstract: The current invention discloses useful pharmaceutical compositions containing azepine derivatives useful as nitric oxide synthase inhibitors.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 29, 1998
    Assignee: G. D. Searle & Co.
    Inventors: Donald W. Hansen, Jr., Mark G. Currie, E. Ann Hallinan, Kam F. Fok, Timothy J. Hagen, Arija A. Bergmanis, Steven W. Kramer, Len F. Lee, Suzanne Metz, William M. Moore, Karen B. Peterson, Barnett S. Pitzele, Dale P. Spangler, R. Keith Webber, Mihaly V. Toth, Mahima Trivedi, Foe S. Tjoeng
  • Human tissue factor inhibitor
    Patent number: 5849875
    Abstract: A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 15, 1998
    Assignee: G. D. Searle & Co.
    Inventors: Tze-Chein Wun, Kuniko K. Kretzmer, George J. Broze, Jr.
  • Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs
    Patent number: 5837698
    Abstract: The present invention relates to a pharmaceutical composition or preparation which comprises hydroxyl containing steroidal hormones and organic nitrite/nitrate or other nitric oxide donating agents.
    Type: Grant
    Filed: May 2, 1996
    Date of Patent: November 17, 1998
    Assignee: G. D. Searle & Co.
    Inventors: Foe S. Tjoeng, Mark G. Currie, Mark E. Zupec
  • Method of attenuating arterial stenosis
    Patent number: 5824644
    Abstract: A method is disclosed for attenuating stenosis after balloon angioplasty. The method comprises administering to a host parenterally or locally to the luminal surface of the blood vessel subjected to said balloon angioplasty an effective amount of tissue factor pathway inhibitor (TFPI) for a prolonged period of time sufficient to substantially reduce the extent of restenosis. An exemplary amount of the TFPI is from about 0.5 mg/kg to about 6 mg/kg during a prolonged administration of about twelve (12) hours to 36 hours.
    Type: Grant
    Filed: July 3, 1996
    Date of Patent: October 20, 1998
    Assignee: G. D. Searle & Co.
    Inventor: Dana R. Abendschein
  • Amidino derivatives useful as nitric oxide synthase inhibitors
    Patent number: 5821267
    Abstract: The current invention discloses amidino derivatives useful as nitric oxide synthase inhibitors.
    Type: Grant
    Filed: March 20, 1996
    Date of Patent: October 13, 1998
    Assignee: G.D. Searle & Co.
    Inventors: Kam F. Fok, Foe S. Tjoeng, R. Keith Webber
  • Recombinant human interleukin-3 (IL-3) multiple mutation polypeptides
    Patent number: 5817486
    Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (a.a.119 to 133) have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 6, 1998
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, John Patrick McKearn, Peter Olafs Olins
  • Expression of heterologous polypeptides from a mini Mu vector
    Patent number: 5814483
    Abstract: A novel chromosomal expression vector based on the bacteriophage Mu is disclosed.
    Type: Grant
    Filed: May 20, 1994
    Date of Patent: September 29, 1998
    Assignee: G. D. Searle & Co.
    Inventors: Robin A. Weinberg, Pamela A. De Ciechi, Mark G. Obukowicz